Evidence-Based Advances in Chronic Spontaneous Urticaria Management in the Hospitalized Patient скачать в хорошем качестве

Evidence-Based Advances in Chronic Spontaneous Urticaria Management in the Hospitalized Patient

In this episode of Hospital Medicine Unplugged, we sprint through urticaria—recognize the wheal, distinguish acute from chronic disease, uncover autoimmune drivers, and step through a modern treatment ladder that now includes biologics and BTK inhibitors. We start with the definition and epidemiology. Urticaria is characterized by transient pruritic wheals, angioedema, or both, typically resolving within 24 hours without scarring. While about 20% of people experience urticaria at some point in life, chronic spontaneous urticaria (CSU) affects roughly 1% of the population and disproportionately affects women aged 30–50. The key classification hinges on duration. • Acute urticaria: symptoms lasting ＜6 weeks • Chronic urticaria: symptoms ≥6 weeks Fortunately, progression from acute to chronic disease occurs in fewer than 8% of cases. Risk factors for chronicity include antithyroid antibodies and poor response to antihistamines. Next comes an important shift in our understanding of etiology. Historically, chronic urticaria was labeled “idiopathic” in most cases. We now know that more than half of patients actually have autoimmune disease mechanisms. Two major autoimmune endotypes exist: Type I autoimmune (autoallergic) CSU • IgE autoantibodies against autoantigens such as thyroid peroxidase or IL-24 • Leads to mast-cell activation similar to allergic disease Type IIb autoimmune CSU • IgG autoantibodies against IgE or the FcεRI receptor • Identified in about 8–10% of patients using strict diagnostic criteria These immune mechanisms explain why less than 35% of CSU cases truly lack detectable autoantibodies. Diagnosis is largely clinical but follows the “7C” framework: Confirm diagnosis, identify causes, assess cofactors, evaluate comorbidities, assess consequences, evaluate biomarkers, and monitor disease course. Routine laboratory testing should remain minimal unless clinical clues suggest otherwise. Recommended baseline tests include: • CBC with differential • ESR or CRP • TSH Certain red flags should trigger referral or further evaluation: • Wheals lasting ＞24 hours • Residual hyperpigmentation after lesions resolve • Angioedema lasting several days without hives • Systemic symptoms such as fever, arthralgia, or abdominal pain To measure disease activity, clinicians rely on validated tools. The Urticaria Activity Score over 7 days (UAS7) is the gold standard. Patients record itch severity and hive count twice daily, producing a score from 0 to 42. Interpretation: • 0: urticaria-free • 1–6: well controlled • 7–15: mild • 16–27: moderate • 28–42: severe The Urticaria Control Test (UCT) is another practical tool. A score ≥12 indicates good control, while ＜12 suggests poorly controlled disease. Management follows a stepwise escalation strategy. Step 1: Second-generation H1 antihistamines Agents include cetirizine, loratadine, fexofenadine, levocetirizine, and desloratadine, taken daily rather than as needed. About 40% of patients achieve meaningful symptom reduction with standard dosing. Step 2: Dose escalation If symptoms persist, antihistamine doses can be increased up to fourfold. Evidence suggests quadrupling the dose of a single antihistamine is more effective than combining multiple agents. Step 3: Omalizumab For antihistamine-refractory disease, omalizumab 300 mg every 4 weeks is the standard biologic therapy. Clinical trials show complete remission (UAS7 = 0) in about 36% of patients, with substantially higher response rates in real-world practice. Patients with incomplete response may require higher doses or shorter dosing intervals. Step 4: Cyclosporine For patients who fail omalizumab, cyclosporine (3–5 mg/kg/day) can improve symptoms in more than half of cases, although monitoring for renal toxicity and hypertension is essential. Short courses of systemic corticosteroids (20–50 mg/day for ＜10 days) may help during severe flares but should never be used long-term. The treatment landscape is expanding rapidly. Two newly approved therapies include: Dupilumab An IL-4 receptor α antagonist approved in 2025 for patients ≥12 years with persistent CSU despite antihistamines. Clinical trials showed complete response in about 31% of patients. Remibrutinib A Bruton tyrosine kinase (BTK) inhibitor approved in 2025 that targets mast-cell signaling downstream of FcεRI activation. Trials demonstrated complete response rates up to ~42% with rapid onset within 2 weeks. Another critical diagnostic consideration is urticarial vasculitis, which can mimic CSU but requires a different approach. Key distinguishing features include: • Lesions lasting ＞24 hours • Pain or burning rather than itching • Residual hyperpigmentation after resolution Systemic symptoms such as fever, arthralgia, or eye inflammation further increase suspicion. Diagnosis is confirmed by skin biopsy showing leukocytoclastic vasculitis. ...